logo

LYKALABS vs WOCKPHARMA: Stock Comparison

LYKALABS vs WOCKHARDTUpdated 1 Jul 26, 4:08 PM ISTNSE & company filings

WOCKHARDT is the larger company by market capitalisation. LYKALABS shows a lower P/E, while WOCKHARDT shows a higher ROE, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

LYKALABS leads 2; WOCKPHARMA leads 7 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

LYKALABSWOCKPHARMA

Valuation lens

What price are you paying?

Market CapContext only
₹308 Cr
₹30,126 Cr
P/E RatioLYKALABS has the lower reading
0x ✓
73.66x
P/B RatioLYKALABS has the lower reading
2.67x ✓
6.1x
EPSWOCKPHARMA has the higher reading
₹0.57
₹6.52 ✓
Book ValueContext only
₹25.12
₹325
Dividend YieldSame reading
0%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
WOCKPHARMA is the larger company
₹30,126 Cr vs ₹308 Cr
P/E Ratio
LYKALABS has a lower P/E
0x vs 73.66x
P/B Ratio
LYKALABS has a lower P/B
2.67x vs 6.1x
EPS
WOCKPHARMA has higher earnings per share
₹6.52 vs ₹0.57
Revenue Growth (TTM YoY)
WOCKPHARMA has faster revenue growth
26% vs 0%
ROE
WOCKPHARMA has a higher ROE
3.77% vs -37.11%
ROCE
WOCKPHARMA has a higher ROCE
5.44% vs -22.29%
Net Margin
WOCKPHARMA has a higher net margin
3.3% vs -7.81%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricLYKALABSWOCKPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricLYKALABSWOCKPHARMA
Live Price₹74.83₹1,855.5
Day Change1.19%-1.16%
Volume88,5564.57 L
52-Week High₹98.9₹2,422.3
52-Week Low₹44.1₹1,086.7
Distance from 52W High-24.34%-23.4%

Valuation

MetricLYKALABSWOCKPHARMA
Market Cap₹308 Cr₹30,126 Cr
P/E Ratio0x73.66x
P/B Ratio2.67x6.1x
EPS₹0.57₹6.52
Book Value₹25.12₹325
Dividend Yield0%0%

Growth

MetricLYKALABSWOCKPHARMA
Revenue Growth (TTM YoY)0%26%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricLYKALABSWOCKPHARMA
ROE-37.11%3.77%
ROCE-22.29%5.44%
Net Margin-7.81%3.3%
Operating Margin-24.74%13.37%
Debt to Equity0.56x0.4x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricLYKALABSWOCKPHARMA
Promoter Holding58.45%49.08%
FII Holding0.15%▼ 0.02 pp7.22%▲ 0.13 pp
DII Holding0.66%9.24%▼ 1.72 pp
Public Holding40.73%▲ 0.01 pp34.44%▲ 1.61 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: LYKALABS and WOCKHARDT.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.